By Gwilym Attwell
Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success and, if applicable, obtaining FDA approval. Intellectual property protection is often further down their list of priorities. This is a mistake.
The strength of a company’s IP assets is a critical factor in determining its value; failure to protect those assets can seriously diminish a company’s prospects for long-term success. Savvy companies focus on IP early and integrate their IP strategies seamlessly into their overall business strategy.